22nd Century Group Shares Dip Slightly on Q4 Revenue Decline Amid Strategic Shift to VLN® Products

22nd Century Group, a biotechnology company focused on nicotine reduction, today announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The company posted net revenues of $3.5 million for the quarter, a 12% decrease compared to the previous year. This figure fell below some analyst expectations, which had anticipated Q4 revenue around $4.05 million to $4.10 million. The company also reported a gross margin of -23.6%.

Despite the revenue challenges, the company highlighted a significant strategic shift during 2025. CEO Larry Firestone emphasized the execution of a pivot toward higher-margin branded products, expanded partnerships with established retail chains, and the development of a new tobacco harm reduction category. Firestone stated, “During 2025, we executed a strategic pivot toward higher-margin branded products, expanded partnerships with established retail chains, and developed a new tobacco harm reduction category, all of which we continue to build upon in 2026.”

Financial Strengthening and VLN® Expansion

A key focus for 22nd Century Group in 2025 was strengthening its financial position. The company successfully exited the year debt-free, having eliminated over $8.0 million of legacy debt through repayment, settlement, and exchange. This effort improved its balance sheet and reduced its cost base. Furthermore, the company finalized an insurance claim related to a 2022 facility fire, securing a $9.5 million non-dilutive settlement, providing crucial capital during its transition. The company ended the calendar year 2025 with $7.1 million in cash.

The expansion of its proprietary VLN® (Very Low Nicotine) products remains central to 22nd Century Group's strategy. The company reported continued expansion of market access for both VLN® and Partner VLN® products, as well as new natural style cigarette products. State authorizations for its branded products increased significantly, with 22nd Century VLN® now authorized in 48 states and Pinnacle® VLN® in 42 states. Pinnacle® VLN® availability specifically increased to nearly 1,500 stores within a top-5 convenience store chain across 12 states, with a full rollout expected within the next 90 days.

Market Reaction and Outlook

In response to the earnings report, 22nd Century Group's stock saw a modest decline of 0.91%, trading at $3.26. This follows a previous close of $3.29. While some sector peers experienced more significant negative moves, XXII's reaction appears largely company-specific.

Looking ahead to 2026, the company's priorities include further expanding VLN® retail distribution and consumer awareness, scaling toward profitability, and maintaining active engagement with FDA regulators and public health stakeholders. Despite analysts forecasting the company to remain unprofitable over the next three years, some projections indicate that 22nd Century Group's revenue could grow faster than the broader U.S. market, potentially at 46.7% per year. The company aims to achieve P&L profitability in the latter half of 2025, a goal that relies on revenue growth, improved gross margins, and cost control.